Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Prod'homme

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Nature Medicine|June 7, 2008
Bench to bedside: tempering antigen-presenting cells in multiple sclerosisThomas Prod'homme, Scott S Zamvil
Cold Spring Harbor Perspectives in Medicine|February 15, 2018
The Evolving Mechanisms of Action of Glatiramer AcetateThomas Prod'homme, Scott S Zamvil
Nature Medicine|April 7, 2007
T effectors outfox T regulators in autoimmunityThomas Prod'homme, Martin S Weber, Scott S Zamvil
Nature Clinical Practice. Neurology|August 26, 2006
Drug Insight: using statins to treat neuroinflammatory diseaseMartin S Weber, Thomas Prod'homme, Lawrence Steinman, et al.
Trends in Immunology|March 15, 2006
A neuropeptide in immune-mediated inflammation, Y?Thomas Prod'homme, Martin S Weber, Lawrence Steinman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 17, 2009
SLAT/Def6 plays a critical role in the development of Th17 cell-mediated experimental autoimmune encephalomyelitisAnn J Canonigo-Balancio, Camille Fos, Thomas Prod'homme, et al.
Journal of Neuroinflammation|February 7, 2014
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunityMartin S Weber, Thomas Prod'homme, Sawsan Youssef, et al.
Expert Opinion on Therapeutic Targets|September 23, 2003
Statins and their potential targets in multiple sclerosis therapyOlaf Stüve, Thomas Prod'homme, Anthony Slavin, et al.
Melanoma Research|December 4, 2004
Class II transactivator (CIITA) isoform expression and activity in melanomaFabrice Baton, Carine Deruyffelaere, Muriel Chapin, et al.
Immunogenetics|October 24, 2003
Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical courseThomas Prod'homme, Benjamin Dekel, Giovanna Barbieri, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Nature Medicine|June 7, 2008
Bench to bedside: tempering antigen-presenting cells in multiple sclerosisThomas Prod'homme, Scott S Zamvil
Cold Spring Harbor Perspectives in Medicine|February 15, 2018
The Evolving Mechanisms of Action of Glatiramer AcetateThomas Prod'homme, Scott S Zamvil
Nature Medicine|April 7, 2007
T effectors outfox T regulators in autoimmunityThomas Prod'homme, Martin S Weber, Scott S Zamvil
Nature Clinical Practice. Neurology|August 26, 2006
Drug Insight: using statins to treat neuroinflammatory diseaseMartin S Weber, Thomas Prod'homme, Lawrence Steinman, et al.
Trends in Immunology|March 15, 2006
A neuropeptide in immune-mediated inflammation, Y?Thomas Prod'homme, Martin S Weber, Lawrence Steinman, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 17, 2009
SLAT/Def6 plays a critical role in the development of Th17 cell-mediated experimental autoimmune encephalomyelitisAnn J Canonigo-Balancio, Camille Fos, Thomas Prod'homme, et al.
Journal of Neuroinflammation|February 7, 2014
Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunityMartin S Weber, Thomas Prod'homme, Sawsan Youssef, et al.
Expert Opinion on Therapeutic Targets|September 23, 2003
Statins and their potential targets in multiple sclerosis therapyOlaf Stüve, Thomas Prod'homme, Anthony Slavin, et al.
Melanoma Research|December 4, 2004
Class II transactivator (CIITA) isoform expression and activity in melanomaFabrice Baton, Carine Deruyffelaere, Muriel Chapin, et al.
Immunogenetics|October 24, 2003
Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical courseThomas Prod'homme, Benjamin Dekel, Giovanna Barbieri, et al.
Pageof 3